로딩 중…
StockDiggingStockDigging

Aprogen Biologics Inc.

003060· KOSPI
₩2,110-6.84%
2026-06-19

Price Chart

Aprogen Biologics Inc.+219.21%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap30.41B KRW
Revenue78.00B KRW
Net Income-131.89B KRW
Total Assets576.99B KRW
Net Assets272.85B KRW
Employees427
Value
P/B0.11x
P/S0.39x
FCF Yield-157.37%
Profitability
ROE-48.34%
ROA-22.86%
Op. Margin-74.66%
Revenue Growth28.33%
Financial Health
Debt Ratio211.47%
Total Debt332.48B KRW
FCF-47.86B KRW
Cash23.76B KRW
Current Ratio0.67x
Performance
1Y Return219.21%
1M Return-34.27%
From 52W High-66.88%
1Y MDD-69.87%
Trading
Volume115,250 shares
Foreign Own.2.41%
Per Share
EPS-9,919 KRW
BPS16,437 KRW

Company Info

CEO 김재섭, 김정출
Employees 427
Founded 1960
HQ 서울특별시 송파구, KR

Aprogen Biologics, founded in 1960, absorbed an affiliate with biopharmaceutical production facilities and technology in 2022, and also incorporated N2TEC, a semiconductor equipment component manufacturer and seller, as a subsidiary. The company's core businesses include pharmaceutical and bio divisions focused on medicine manufacturing and sales, as well as semiconductor equipment component production. Its Osong factory boasts the world's fifth-largest antibody production capacity and collaborates with Aprogen on the production and commercialization of biosimilar medicines. Aprogen Biologics is headquartered in Songpa-gu, Seoul.